In pancreatic cancer cell lines and resistant cell lines, overexpression of Kras and simultaneous knockdown of MACC1-AS1 or knockdown of Kras and simultaneous overexpression of MACC1-AS1 resulted in different levels of drug resistance. This evidence concerns the gene KRAS and familial pancreatic carcinoma.